LV11183B - Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof - Google Patents

Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof Download PDF

Info

Publication number: LV11183B
Authority: LV; Latvia
Prior art keywords: esters; derivative; hydroxy; active ingredient; des
Prior art date: 1990-11-12

Application number

LVP-95-341A

Other languages

English (en)

Latvian (lv)

Other versions

LV11183A (lv

Inventor

Michel Lanquetin

Original Assignee

Theramex

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-12

Filing date

1995-11-14

Publication date

1996-10-20

1995-11-14 Application filed by Theramex filed Critical Theramex

1996-04-20 Publication of LV11183A publication Critical patent/LV11183A/xx

1996-10-20 Publication of LV11183B publication Critical patent/LV11183B/lv

Links

238000000034 method Methods 0.000 title claims abstract description 36
230000008569 process Effects 0.000 title claims abstract description 11
230000003637 steroidlike Effects 0.000 title claims abstract 5
239000008194 pharmaceutical composition Substances 0.000 title claims 6
239000000126 substance Substances 0.000 title description 11
239000000203 mixture Substances 0.000 claims abstract description 37
239000002904 solvent Substances 0.000 claims abstract description 20
239000004094 surface-active agent Substances 0.000 claims abstract description 9
238000002425 crystallisation Methods 0.000 claims abstract 4
238000009835 boiling Methods 0.000 claims abstract 3
230000008025 crystallization Effects 0.000 claims abstract 3
239000013078 crystal Substances 0.000 claims abstract 2
150000002148 esters Chemical class 0.000 claims description 35
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 24
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 21
229960005309 estradiol Drugs 0.000 claims description 13
229930182833 estradiol Natural products 0.000 claims description 13
229960004911 nomegestrol Drugs 0.000 claims description 13
KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 claims description 13
239000000186 progesterone Substances 0.000 claims description 13
229960003604 testosterone Drugs 0.000 claims description 13
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 12
229960003387 progesterone Drugs 0.000 claims description 11
-1 testosterone ethers Chemical class 0.000 claims description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
229960004719 nandrolone Drugs 0.000 claims description 8
229960003957 dexamethasone Drugs 0.000 claims description 7
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims description 7
150000002170 ethers Chemical class 0.000 claims description 5
229960004618 prednisone Drugs 0.000 claims description 5
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 5
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 4
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 4
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 4
XIIAYQZJNBULGD-LDHZKLTISA-N cholestane Chemical group C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 claims description 4
229960004544 cortisone Drugs 0.000 claims description 4
GTFUITFQDGVJSK-XGXHKTLJSA-N gestonorone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 GTFUITFQDGVJSK-XGXHKTLJSA-N 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 3
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
229960003399 estrone Drugs 0.000 claims description 3
150000002367 halogens Chemical group 0.000 claims description 3
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 2
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 2
229960001348 estriol Drugs 0.000 claims description 2
229940064748 medrol Drugs 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
229960005294 triamcinolone Drugs 0.000 claims description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 13
150000001875 compounds Chemical class 0.000 claims 6
JWMFYGXQPXQEEM-WZBAXQLOSA-N pregnane Chemical class C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 JWMFYGXQPXQEEM-WZBAXQLOSA-N 0.000 claims 4
150000001440 androstane derivatives Chemical group 0.000 claims 3
235000014113 dietary fatty acids Nutrition 0.000 claims 3
229930195729 fatty acid Natural products 0.000 claims 3
239000000194 fatty acid Substances 0.000 claims 3
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims 2
125000005907 alkyl ester group Chemical group 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 2
239000003945 anionic surfactant Substances 0.000 claims 2
229960002537 betamethasone Drugs 0.000 claims 2
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 2
239000011877 solvent mixture Substances 0.000 claims 2
150000003515 testosterones Chemical class 0.000 claims 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
235000021355 Stearic acid Nutrition 0.000 claims 1
150000001335 aliphatic alkanes Chemical class 0.000 claims 1
239000011230 binding agent Substances 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 claims 1
229920001577 copolymer Polymers 0.000 claims 1
239000003246 corticosteroid Substances 0.000 claims 1
150000004292 cyclic ethers Chemical class 0.000 claims 1
150000005690 diesters Chemical group 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
150000002081 enamines Chemical group 0.000 claims 1
VOXZDWNPVJITMN-WKUFJEKOSA-N estradiol group Chemical group [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
150000004665 fatty acids Chemical class 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
239000012456 homogeneous solution Substances 0.000 claims 1
150000002576 ketones Chemical class 0.000 claims 1
239000002736 nonionic surfactant Substances 0.000 claims 1
231100000252 nontoxic Toxicity 0.000 claims 1
230000003000 nontoxic effect Effects 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
239000002798 polar solvent Substances 0.000 claims 1
239000008117 stearic acid Substances 0.000 claims 1
150000003431 steroids Chemical group 0.000 claims 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 26
239000003795 chemical substances by application Substances 0.000 description 16
229920001213 Polysorbate 20 Polymers 0.000 description 13
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 13
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 13
230000007704 transition Effects 0.000 description 12
238000004090 dissolution Methods 0.000 description 10
238000010992 reflux Methods 0.000 description 10
239000000725 suspension Substances 0.000 description 9
239000002775 capsule Substances 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
239000008101 lactose Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
240000008042 Zea mays Species 0.000 description 5
235000002017 Zea mays subsp mays Nutrition 0.000 description 5
230000006978 adaptation Effects 0.000 description 5
230000003321 amplification Effects 0.000 description 5
GRXPVLPQNMUNNX-MHJRRCNVSA-N estrane Chemical compound C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 GRXPVLPQNMUNNX-MHJRRCNVSA-N 0.000 description 5
230000004927 fusion Effects 0.000 description 5
239000000499 gel Substances 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
ALSXNTIVNJBNQE-ZWONNITHSA-N (8r,9r,10s,13r,14s,17s)-17-ethyl-13-methyl-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthrene Chemical compound C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 ALSXNTIVNJBNQE-ZWONNITHSA-N 0.000 description 4
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 4
JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 description 4
229920003084 Avicel® PH-102 Polymers 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
235000005822 corn Nutrition 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 description 3
NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
238000013019 agitation Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002131 composite material Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
229940082150 encore Drugs 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000012986 modification Methods 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229960004765 promestriene Drugs 0.000 description 3
IUWKNLFTJBHTSD-AANPDWTMSA-N promestriene Chemical compound C1C[C@]2(C)[C@@H](OC)CC[C@H]2[C@@H]2CCC3=CC(OCCC)=CC=C3[C@H]21 IUWKNLFTJBHTSD-AANPDWTMSA-N 0.000 description 3
206010012289 Dementia Diseases 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
229960003473 androstanolone Drugs 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
229960002899 hydroxyprogesterone Drugs 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
238000012546 transfer Methods 0.000 description 2
CPUKWYXYHPOQJH-RDQPJNLGSA-N (8r,9s,10s,13s,14s)-17-ethenyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(=CC4)C=C)[C@@H]4[C@@H]3CCC21 CPUKWYXYHPOQJH-RDQPJNLGSA-N 0.000 description 1
MIZLGWKEZAPEFJ-UHFFFAOYSA-N 1,1,2-trifluoroethene Chemical group FC=C(F)F MIZLGWKEZAPEFJ-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
QFMDFTQOJHFVNR-UHFFFAOYSA-N 1-[2,2-dichloro-1-(4-ethylphenyl)ethyl]-4-ethylbenzene Chemical compound C1=CC(CC)=CC=C1C(C(Cl)Cl)C1=CC=C(CC)C=C1 QFMDFTQOJHFVNR-UHFFFAOYSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
125000002458 19-norprogesterone group Chemical group 0.000 description 1
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 description 1
235000011331 Brassica Nutrition 0.000 description 1
241000219198 Brassica Species 0.000 description 1
101100402341 Caenorhabditis elegans mpk-1 gene Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
MAMMVUWCKMOLSG-UHFFFAOYSA-N Cyclohexyl propionate Chemical compound CCC(=O)OC1CCCCC1 MAMMVUWCKMOLSG-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
241000052343 Dares Species 0.000 description 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
240000005926 Hamelia patens Species 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
244000147568 Laurus nobilis Species 0.000 description 1
235000017858 Laurus nobilis Nutrition 0.000 description 1
240000005265 Lupinus mutabilis Species 0.000 description 1
235000008755 Lupinus mutabilis Nutrition 0.000 description 1
206010029897 Obsessive thoughts Diseases 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
235000019095 Sechium edule Nutrition 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
235000005212 Terminalia tomentosa Nutrition 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
241000609666 Tuber aestivum Species 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
DPHFJXVKASDMBW-RQRKFSSASA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O DPHFJXVKASDMBW-RQRKFSSASA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229960003840 cortivazol Drugs 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
239000001064 degrader Substances 0.000 description 1
239000002781 deodorant agent Substances 0.000 description 1
230000008021 deposition Effects 0.000 description 1
235000021185 dessert Nutrition 0.000 description 1
229960003657 dexamethasone acetate Drugs 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000007519 figuring Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
229960004616 medroxyprogesterone Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000003607 modifier Substances 0.000 description 1
235000011929 mousse Nutrition 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N phenyl acetate Chemical compound CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
150000003146 progesterones Chemical class 0.000 description 1
239000002964 rayon Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
230000007958 sleep Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
108010012137 spleen derived immunosuppressive peptide Proteins 0.000 description 1
229960000351 terfenadine Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000017105 transposition Effects 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0025—Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0077—Ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LVP-95-341A 1990-11-12 1995-11-14 Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof LV11183B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9013981A FR2668945B1 (fr)	1990-11-12	1990-11-12	Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.

Publications (2)

Publication Number	Publication Date
LV11183A LV11183A (lv)	1996-04-20
LV11183B true LV11183B (en)	1996-10-20

Family

ID=9402062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-95-341A LV11183B (en)	1990-11-12	1995-11-14	Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof

Country Status (17)

Country	Link
US (1)	US5266712A (de)
EP (1)	EP0510167B1 (de)
JP (1)	JP3281954B2 (de)
KR (1)	KR100196895B1 (de)
AT (1)	ATE126806T1 (de)
BR (1)	BR9106012A (de)
CA (1)	CA2073760C (de)
DE (1)	DE69112379T2 (de)
DK (1)	DK0510167T3 (de)
ES (1)	ES2079172T3 (de)
FI (1)	FI111545B (de)
FR (1)	FR2668945B1 (de)
GR (1)	GR3018117T3 (de)
HU (1)	HU212780B (de)
LV (1)	LV11183B (de)
RU (1)	RU2126013C1 (de)
WO (1)	WO1992008730A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2776191B1 (fr) *	1998-03-23	2002-05-31	Theramex	Composition hormonale topique a effet systemique
US6432936B1 (en)	1999-01-20	2002-08-13	Wisconsin Alumni Research Foundation	Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US8980290B2 (en)	2000-08-03	2015-03-17	Antares Pharma Ipl Ag	Transdermal compositions for anticholinergic agents
WO2002011768A1 (en)	2000-08-03	2002-02-14	Antares Pharma Ipl Ag	Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en)	2000-08-03	2007-04-03	Antares Pharma Ipl Ag	Formulations for transdermal or transmucosal application
WO2005039531A1 (en)	2003-10-10	2005-05-06	Antares Pharma Ipl Ag	Transdermal pharmaceutical formulation for minimizing skin residues
DK1361881T3 (da) *	2000-12-14	2006-02-20	Ortho Mcneil Pharm Inc	Steroide hormonprodukter og fremgangsmåder til fremstilling heraf
DE10152351B4 (de) *	2001-10-18	2005-09-22	Schering Ag	Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE10218107A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218106A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
MY143936A (en)	2003-03-27	2011-07-29	Nycomed Gmbh	Process for preparing crystalline ciclesonide with defined particle size
EP1727520A2 (de) *	2003-12-09	2006-12-06	Medcrystalforms, Llc	Verfahren zur herstellung von mischphasen-kokristallen mit wirkstoffen
WO2005074942A1 (en) *	2004-02-04	2005-08-18	Retmed Pty Ltd	Slow release steroid composition
RU2253453C1 (ru) *	2004-03-15	2005-06-10	Общество с ограниченной ответственностью "ЮНАЛ"	Противовоспалительная и антиаллергическая композиция
US7425340B2 (en)	2004-05-07	2008-09-16	Antares Pharma Ipl Ag	Permeation enhancing compositions for anticholinergic agents
US20060058276A1 (en) *	2004-07-15	2006-03-16	Oded Friedman	Processes for the preparation and purification of rocuronium bromide
WO2006125642A1 (en)	2005-05-27	2006-11-30	Antares Pharma Ipl Ag	Methods and apparatus for transdermal or transmucosal application of testosterone
NZ571460A (en)	2006-04-21	2010-10-29	Antares Pharma Ipl Ag	Methods of treating hot flashes with formulations for transdermal or transmucosal application
EP1931682A2 (de) *	2006-08-03	2008-06-18	Teva Pharmaceutical Industries Ltd.	Verfahren zur herstellung von clopidogrel-bisulphat
CN101961311B (zh) *	2010-09-21	2012-11-21	中山大学	一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
MX393195B (es) *	2012-06-18	2025-03-24	Therapeuticsmd Inc	Capsula de estradiol soluble para insercion por via vaginal
CN112871079B (zh) *	2021-01-27	2023-05-16	丽江映华生物药业有限公司	醋酸诺美孕酮微粒的制备方法及制备装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2096744A (en) *	1932-10-27	1937-10-26	Schering Corp	Hydrogenation products of follicle hormones and method of producing same
US2361847A (en) *	1937-09-04	1944-10-31	Schering Corp	Aromatization of steroid compounds and more especially to the production of estrone-and estradiollike compounds and of their derivatives from delta 1, 2, 4, 5-androstadienol-17-one-3
US2897216A (en) *	1954-11-01	1959-07-28	Schering Corp	Process for the preparation of steroidal dienes and intermediates obtained thereby
US3053865A (en) *	1958-03-19	1962-09-11	Merck & Co Inc	Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) *	1959-01-22	1961-11-07	Lab Francais Chimiotherapie	Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3836628A (en)	1972-05-22	1974-09-17	Int Research & Dev Co Ltd	Crystal growth modifier
DE2323812A1 (de) *	1973-05-11	1974-11-28	Jenapharm Veb	Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe
GB1515284A (en) *	1974-05-21	1978-06-21	Gastaud J	Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
US4634694A (en) *	1984-01-14	1987-01-06	Akzo N.V.	Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4795747A (en) *	1985-12-23	1989-01-03	Latman Neal S	16-epiestriol to prevent, inhibit or reduce inflammation
US4956600A (en) *	1988-07-01	1990-09-11	Viteq Corporation	High frequency current detector for a low frequency line

1990
- 1990-11-12 FR FR9013981A patent/FR2668945B1/fr not_active Expired - Fee Related
1991
- 1991-11-12 JP JP50041592A patent/JP3281954B2/ja not_active Expired - Lifetime
- 1991-11-12 RU SU5052919A patent/RU2126013C1/ru active
- 1991-11-12 CA CA002073760A patent/CA2073760C/fr not_active Expired - Lifetime
- 1991-11-12 AT AT92900237T patent/ATE126806T1/de not_active IP Right Cessation
- 1991-11-12 WO PCT/FR1991/000888 patent/WO1992008730A1/fr not_active Ceased
- 1991-11-12 BR BR919106012A patent/BR9106012A/pt not_active Application Discontinuation
- 1991-11-12 ES ES92900237T patent/ES2079172T3/es not_active Expired - Lifetime
- 1991-11-12 EP EP92900237A patent/EP0510167B1/de not_active Expired - Lifetime
- 1991-11-12 US US07/910,284 patent/US5266712A/en not_active Expired - Lifetime
- 1991-11-12 DE DE69112379T patent/DE69112379T2/de not_active Expired - Lifetime
- 1991-11-12 KR KR1019920701658A patent/KR100196895B1/ko not_active Expired - Lifetime
- 1991-11-12 HU HU9202608A patent/HU212780B/hu unknown
- 1991-11-12 DK DK92900237.6T patent/DK0510167T3/da active
1992
- 1992-07-10 FI FI923188A patent/FI111545B/fi not_active IP Right Cessation
1995
- 1995-11-14 LV LVP-95-341A patent/LV11183B/lv unknown
- 1995-11-20 GR GR950403233T patent/GR3018117T3/el unknown

Also Published As

Publication number	Publication date
JP3281954B2 (ja)	2002-05-13
HU212780B (en)	1996-11-28
DE69112379D1 (de)	1995-09-28
GR3018117T3 (en)	1996-02-29
RU2126013C1 (ru)	1999-02-10
EP0510167A1 (de)	1992-10-28
FR2668945A1 (fr)	1992-05-15
US5266712A (en)	1993-11-30
KR927003617A (ko)	1992-12-18
DK0510167T3 (da)	1996-01-02
CA2073760C (fr)	2003-09-23
JPH05503305A (ja)	1993-06-03
ES2079172T3 (es)	1996-01-01
KR100196895B1 (ko)	1999-06-15
HUT61319A (en)	1992-12-28
BR9106012A (pt)	1993-01-05
FR2668945B1 (fr)	1993-02-19
DE69112379T2 (de)	1996-03-28
ATE126806T1 (de)	1995-09-15
LV11183A (lv)	1996-04-20
HU9202608D0 (en)	1992-10-28
FI923188L (fi)	1992-07-10
CA2073760A1 (fr)	1992-05-13
FI111545B (fi)	2003-08-15
EP0510167B1 (de)	1995-08-23
WO1992008730A1 (fr)	1992-05-29
FI923188A0 (fi)	1992-07-10

Publication	Publication Date	Title
EP0510167B1 (de)	1995-08-23	Neues kristallisationsverfahren von steroidverbindungen und so produzierte verbindungen
EP2085075B1 (de)	2016-09-28	Stabile geformte Partikel von kristallinen organischen Verbindungen
EP0674900A1 (de)	1995-10-04	Transdermales Matrixsystem auf EVA Basis zur Verabreichung eines Östrogens und/oder Gestagens
LU88001A1 (fr)	1992-06-01	Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires
CN104861023A (zh)	2015-08-26	用于获得11-脱氧皮醇的17α-单酯和/或其9,11-脱氢衍生物的酶法
JP2002518514A (ja)	2002-06-25	テストステロン誘導体
EP0852492A1 (de)	1998-07-15	Trandermales matrixsystem
JPS61118315A (ja)	1986-06-05	ステロイド−１７−モノエステル含有クリ−ム剤
JP2001509487A (ja)	2001-07-24	ペプチケミオを含有する薬剤学的組成物
CA2489708A1 (en)	2003-12-24	A process for the preparation of piroxicam: .beta.-cyclodextrin inclusion compounds
US3764616A (en)	1973-10-09	21-phosphate esters of 17{60 -acyloxy-21 hydroxy steroids of the pregnane series
JP2009137922A (ja)	2009-06-25	リファマイシン誘導体を傷害組織にデリバリーする製剤
KR100788449B1 (ko)	2008-01-02	덱시부프로펜 현탁원료 및 현탁액제의 제조방법
EP0950050A1 (de)	1999-10-20	Verfahren zur kristallisierung eines tetrahydropyridinderivates und die so erhaltenen kristallinen formen
HK1155384B (en)	2013-05-16	Stable shaped particles of crystalline organic compounds
PT100315B (pt)	1999-06-30	Processo para a cristalizacao de substancias organicas de origem esteroidiana e os compostos assim obtidos
JPH0129199B2 (de)	1989-06-08
IL101260A (en)	1996-01-19	Crystallization of organic substances of steroidal origin and the thus obtained compounds
IE920850A1 (en)	1993-09-22	Novel process for crystallizing the organic substances from¹steroidal origin and the thus obtained compounds
AU2012227181A1 (en)	2012-10-11	Direct Dissolution Of Docetaxel In A Solvent In Polysorbate 80
CN101514180A (zh)	2009-08-26	培哚普利叔丁铵盐的ⅰ晶型及其制备方法
MXPA01006048A (en)	2002-06-05	Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions